Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan.

ABSTRACT:

Background

This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients.

Methods

A clinical pilot study was designed in which patients with ulcer and/or pain at rest were treated with bosentan p.o. at a dose of 62.5 mg twice daily during the first month, which was thereafter up-titrated to 125 mg twice daily. The study endpoints were clinical improvement rate, major or minor amputation rate, haemodynamic changes, changes in endothelial function and angiographic changes.

Results

Seven out of 12 patients were male (58%). Median age was 39 years (range 29-49). The median follow-up was 20 months (range 11-40). All patients were smokers. With bosentan treatment, new ischaemic lesions were observed

SUBMITTER: De Haro J 

PROVIDER: S-EPMC3306190 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature